- Diagnostics
- Monday, 13 Apr 2020
Huami partners with Nanshan Zhong's team to fight COVID-19 coronavirus in a joint laboratory
Huami announced a collaboration with the Chinese National Center for Clinical Research on Lung Disease (NCRCRD) and the Guangdong Nanshan Institute for Medical Innovation, led by Dr. Nanshan Zhong, to establish a joint laboratory to develop smart portable devices. Relying on Huami's intelligent portable technologies and powerful calculation algorithms, the laboratory aims to help monitor and manage COVID-19 cured patients through the NCRCRD big data platform. In addition, the laboratory would jointly contribute to an alert and forecast system for epidemics.
"As a collaboration between medical institutes, research and development institutions and companies, we are excited to use our expertise in intelligent portable technologies to promote applied research and facilitate a real transformation in respiratory health" said Wang Huang , founder and chief executive officer of Huami Technology. Guided by its mission to “connect health to technology”, Huami is determined to create a global health ecosystem including devices, data and services, while being a trusted trusted partner of its users.
Dr Nanshan Zhong, 83, an internationally renowned respiratory specialist and member of the Chinese Academy of Engineering, was a pioneer in the fight against SARS in 2013 and is now the chief expert on COVID-19 prevention with the Chinese National Health Commission. Dr. Nanshan Zhong has been fighting on the front line of the coronavirus epidemic since he reported the first person-to-person transmission of COVID-19 in January.
Since the onset of the coronavirus epidemic, Huami has continued its efforts to "connect health to technology". The company has donated RMB 11.5 million worth of medical supplies and equipment since the start of the epidemic. Huami also developed a smart watch for medical personnel in Wuhan , which has a function to alleviate psychological distress.
Related Industry Updates
North America Cancer tissue diagnostics market is expected to reach US$ 4,350 million by 2027 with CAGR of 8%.
Oct 20, 2020
Conduent: Disease Surveillance and Outbreak Management System to Fight Coronavirus
Feb 19, 2020
ZEUS Scientific Announces New Rapid SARS-CoV-2 Antibody Test
Apr 23, 2020
PSA Test Explained: What It Is, How It Works, and Why It Matters
Mar 27, 2026
CVS Health to Significantly Expand COVID-19 Testing Capabilities
Apr 28, 2020
OPKO Health's BioReference Laboratories in Partnership with New York State Initiates Testing for COVID-19 Antibodies
Apr 30, 2020
Phosphorus Announces In-Home COVID-19 Viral And Antibody Testing Service In New York Metropolitan Area
May 19, 2020